👌_老虎社区_美港股上老虎

2021-12-19

👌

US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week<blockquote>美国IPO每周回顾：6家IPO在假期周缩短前首次亮相</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":699427795,"tweetId":"699427795","gmtCreate":1639880341352,"gmtModify":1639880341681,"author":{"id":3581903045598734,"idStr":"3581903045598734","authorId":3581903045598734,"authorIdStr":"3581903045598734","name":"Kong06","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":30,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>👌&nbsp;</body></html>","htmlText":"<html><head></head><body>👌&nbsp;</body></html>","text":"👌","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699427795","repostId":1104728154,"repostType":4,"repost":{"id":"1104728154","kind":"news","pubTimestamp":1639803394,"share":"https://www.laohu8.com/m/news/1104728154?lang=zh_CN&edition=full","pubTime":"2021-12-18 12:56","market":"us","language":"en","title":"US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week<blockquote>美国IPO每周回顾：6家IPO在假期周缩短前首次亮相</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104728154","media":"renaissancecap...","summary":"The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by I","content":"The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer&nbsp;Samsara(IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings.<blockquote>过去一周IPO市场的活动有所增加，由物联网解决方案开发商牵头的六起IPO筹集了9.19亿美元轮回（物联网）。14家SPAC也上市了。该管道得到了推动，六家IPO和三家SPAC提交了初始文件。</blockquote> <a href=\"https://laohu8.com/S/IOT\">Samsara</a> priced at the high end to raise $805 million at a $12.4 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22. Samsara finished down 3%.<blockquote><a href=\"https://laohu8.com/S/IOT\">轮回</a>定价高端，以124亿美元的市值筹集8.05亿美元。这家“物联网”公司提供了一个基于云的平台，将企业的资产与物理运营连接起来，提高了运营效率以及资产和员工的生产力。Samsara增长迅速，但利润极低，在2022财年第9个月，ARR超过10万美元的客户实现了两位数增长。Samsara收盘下跌3%。</blockquote> Italian solid tumor biotech&nbsp;<a href=\"https://laohu8.com/S/GNTA\">Genenta Science</a> upsized and priced at the midpoint to raise $36 million at a $208 million market cap. Genenta’s lead candidate, Temferon, is currently in a Phase 1/2a dose-escalation trial in newly diagnosed glioblastoma multiforme patients with unmethylated MGMT gene promoters. The company anticipates completing patient enrollment and treatment by the 2Q22. Genenta finished down 4%.<blockquote>意大利实体瘤生物技术<a href=\"https://laohu8.com/S/GNTA\">Genenta科学</a>扩大规模并以中点定价，以2.08亿美元的市值筹集3600万美元。Genenta的主要候选药物Temferon目前正在对新诊断的MGMT基因启动子未甲基化的多形性胶质母细胞瘤患者进行1/2a期剂量递增试验。该公司预计将完成2022年第二季度的患者招募和治疗。Genenta收盘下跌4%。</blockquote> Wine brand&nbsp;<a href=\"https://laohu8.com/S/VINE\">Fresh Vine Wine&nbsp;</a> priced at the high end to raise $22 million at a $122 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico. Fresh Vine Wine finished down 43%.<blockquote>葡萄酒品牌<a href=\"https://laohu8.com/S/VINE\">鲜藤酒 </a>定价高端，以1.22亿美元的市值筹集2200万美元。这家名人创立的公司生产低碳水化合物、低热量的优质葡萄酒。Fresh Vine通过批发、零售和DTC渠道销售其葡萄酒，并能够在所有50个州和波多黎各进行批发分销。鲜藤葡萄酒收盘下跌43%。</blockquote> Micro-cap&nbsp;<a href=\"https://laohu8.com/S/IMMX\">Immix Biopharma</a> priced at the low end to raise $21 million at a $71 million market cap. Immix Biopharma is developing a novel class of tissue-specific therapies in oncology and inflammation. Its lead candidate, IMX-110, is currently in Phase 1b/2a trials for solid tumors in the US and Australia. Immix finished down 20%.<blockquote>微帽<a href=\"https://laohu8.com/S/IMMX\">Immix生物制药</a>定价较低，以7100万美元的市值筹集2100万美元。Immix Biopharma正在开发一种新型的肿瘤学和炎症组织特异性疗法。其主要候选药物IMX-110目前正在美国和澳大利亚进行实体瘤的1b/2a期试验。Immix收盘下跌20%。</blockquote> Australia-listed&nbsp;<a href=\"https://laohu8.com/S/BNOX\">Bionomics</a> raised $20 million at an $89 million market cap. Bionomics’ lead candidate, BNC210, is expected to begin its Phase 2 PREVAIL trial for social anxiety disorder by the end of 2021, with topline data anticipated by the end of 2022, and has already started its Phase 2b ATTUNE trial for PTSD, with topline data anticipated in the 1H23. Bionomics finished up 5%.<blockquote>澳洲上市<a href=\"https://laohu8.com/S/BNOX\">生物经济学</a>以8900万美元的市值筹集了2000万美元。Bionomics的主要候选药物BNC210预计将于2021年底开始针对社交焦虑症的2期PREVAIL试验，预计将于2022年底获得顶线数据，并且已经开始针对PTSD的2b期ATTUNE试验，预计将于2023年上半年获得顶线数据。Bionomics收盘上涨5%。</blockquote> Micro-cap satellite developer&nbsp;<a href=\"https://laohu8.com/S/SIDU\">Sidus Space&nbsp;</a> priced at the midpoint to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21. Sidus Space finished up 133%.<blockquote>微型卫星开发商<a href=\"https://laohu8.com/S/SIDU\">Sidus空间 </a>定价中点，以8100万美元的市值筹集1500万美元。这家公司提供设计、制造、发射和数据收集等商业卫星服务。迄今为止，Sidus Space已产生与太空相关的制造收入，但2021年9月毛利率为负，严重无利可图。Sidus Space收盘上涨133%。</blockquote> 14 SPACs went public led by electrification-focused&nbsp;Battery Future Acquisition(BFAC.U) and Investcorp’s&nbsp;Investcorp Europe Acquisition I(IVCBU), which both raised $300 million.<blockquote>以电气化为重点的14家SPAC上市电池未来收购(BFAC.U)和Investcorp的Investcorp欧洲收购I(IVCBU)，均筹集了3亿美元。</blockquote> <img src=\"https://static.tigerbbs.com/799a4a1f3d2f8a7ae87a4d79ea13c453\" tg-width=\"481\" tg-height=\"577\" referrerpolicy=\"no-referrer\">Six IPOs submitted initial filings led by leading PE firmTPG(TPG), which filed for an estimated $1.5 billion IPO. ALS biotech&nbsp;Amylyx Pharmaceuticals(AMLX), software firmJustworks(JW), and hypertension biotech&nbsp;CinCor Pharma(CINC) all filed to raise $100 million. Chinese food and beverage supplier&nbsp;Fortune Valley Treasures(FVTI) filed to raise $25 million, and cybersecurity services provider&nbsp;Cerberus Cyber Sentinel(CISO) filed to raise $10 million.<blockquote>由领先私募股权公司牵头的六家IPO提交了初始文件TPG(TPG)，该公司申请了估计15亿美元的IPO。作为生物技术Amylyx制药公司(AMLX)，软件公司Justworks（JW）和高血压生物技术辛科尔制药公司(CINC)均申请筹集1亿美元。中式餐饮供应商财富谷宝藏(FVTI)申请筹集2500万美元，网络安全服务提供商地狱犬网络哨兵（CISO）申请筹集1000万美元。</blockquote> Three SPACs submitted initial filings led by Sagansky and Sloan’s&nbsp;Screaming Eagle Acquisition(SCRMU), which filed to raise $750 million.<blockquote>三家SPAC提交了由Sagansky和Sloan's牵头的初始文件尖叫鹰收购(SCRMU)，申请筹集7.5亿美元。</blockquote> <img src=\"https://static.tigerbbs.com/d7c4fbba2b60c3e616cb443ad97fd1a9\" tg-width=\"710\" tg-height=\"418\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week<blockquote>美国IPO每周回顾：6家IPO在假期周缩短前首次亮相</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week<blockquote>美国IPO每周回顾：6家IPO在假期周缩短前首次亮相</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nrenaissancecap...2021-12-18 12:56\n\n</h4>\n</header>\n<article>\nThe IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer&nbsp;Samsara(IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings.<blockquote>过去一周IPO市场的活动有所增加，由物联网解决方案开发商牵头的六起IPO筹集了9.19亿美元轮回（物联网）。14家SPAC也上市了。该管道得到了推动，六家IPO和三家SPAC提交了初始文件。</blockquote> <a href=\"https://laohu8.com/S/IOT\">Samsara</a> priced at the high end to raise $805 million at a $12.4 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22. Samsara finished down 3%.<blockquote><a href=\"https://laohu8.com/S/IOT\">轮回</a>定价高端，以124亿美元的市值筹集8.05亿美元。这家“物联网”公司提供了一个基于云的平台，将企业的资产与物理运营连接起来，提高了运营效率以及资产和员工的生产力。Samsara增长迅速，但利润极低，在2022财年第9个月，ARR超过10万美元的客户实现了两位数增长。Samsara收盘下跌3%。</blockquote> Italian solid tumor biotech&nbsp;<a href=\"https://laohu8.com/S/GNTA\">Genenta Science</a> upsized and priced at the midpoint to raise $36 million at a $208 million market cap. Genenta’s lead candidate, Temferon, is currently in a Phase 1/2a dose-escalation trial in newly diagnosed glioblastoma multiforme patients with unmethylated MGMT gene promoters. The company anticipates completing patient enrollment and treatment by the 2Q22. Genenta finished down 4%.<blockquote>意大利实体瘤生物技术<a href=\"https://laohu8.com/S/GNTA\">Genenta科学</a>扩大规模并以中点定价，以2.08亿美元的市值筹集3600万美元。Genenta的主要候选药物Temferon目前正在对新诊断的MGMT基因启动子未甲基化的多形性胶质母细胞瘤患者进行1/2a期剂量递增试验。该公司预计将完成2022年第二季度的患者招募和治疗。Genenta收盘下跌4%。</blockquote> Wine brand&nbsp;<a href=\"https://laohu8.com/S/VINE\">Fresh Vine Wine&nbsp;</a> priced at the high end to raise $22 million at a $122 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico. Fresh Vine Wine finished down 43%.<blockquote>葡萄酒品牌<a href=\"https://laohu8.com/S/VINE\">鲜藤酒 </a>定价高端，以1.22亿美元的市值筹集2200万美元。这家名人创立的公司生产低碳水化合物、低热量的优质葡萄酒。Fresh Vine通过批发、零售和DTC渠道销售其葡萄酒，并能够在所有50个州和波多黎各进行批发分销。鲜藤葡萄酒收盘下跌43%。</blockquote> Micro-cap&nbsp;<a href=\"https://laohu8.com/S/IMMX\">Immix Biopharma</a> priced at the low end to raise $21 million at a $71 million market cap. Immix Biopharma is developing a novel class of tissue-specific therapies in oncology and inflammation. Its lead candidate, IMX-110, is currently in Phase 1b/2a trials for solid tumors in the US and Australia. Immix finished down 20%.<blockquote>微帽<a href=\"https://laohu8.com/S/IMMX\">Immix生物制药</a>定价较低，以7100万美元的市值筹集2100万美元。Immix Biopharma正在开发一种新型的肿瘤学和炎症组织特异性疗法。其主要候选药物IMX-110目前正在美国和澳大利亚进行实体瘤的1b/2a期试验。Immix收盘下跌20%。</blockquote> Australia-listed&nbsp;<a href=\"https://laohu8.com/S/BNOX\">Bionomics</a> raised $20 million at an $89 million market cap. Bionomics’ lead candidate, BNC210, is expected to begin its Phase 2 PREVAIL trial for social anxiety disorder by the end of 2021, with topline data anticipated by the end of 2022, and has already started its Phase 2b ATTUNE trial for PTSD, with topline data anticipated in the 1H23. Bionomics finished up 5%.<blockquote>澳洲上市<a href=\"https://laohu8.com/S/BNOX\">生物经济学</a>以8900万美元的市值筹集了2000万美元。Bionomics的主要候选药物BNC210预计将于2021年底开始针对社交焦虑症的2期PREVAIL试验，预计将于2022年底获得顶线数据，并且已经开始针对PTSD的2b期ATTUNE试验，预计将于2023年上半年获得顶线数据。Bionomics收盘上涨5%。</blockquote> Micro-cap satellite developer&nbsp;<a href=\"https://laohu8.com/S/SIDU\">Sidus Space&nbsp;</a> priced at the midpoint to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21. Sidus Space finished up 133%.<blockquote>微型卫星开发商<a href=\"https://laohu8.com/S/SIDU\">Sidus空间 </a>定价中点，以8100万美元的市值筹集1500万美元。这家公司提供设计、制造、发射和数据收集等商业卫星服务。迄今为止，Sidus Space已产生与太空相关的制造收入，但2021年9月毛利率为负，严重无利可图。Sidus Space收盘上涨133%。</blockquote> 14 SPACs went public led by electrification-focused&nbsp;Battery Future Acquisition(BFAC.U) and Investcorp’s&nbsp;Investcorp Europe Acquisition I(IVCBU), which both raised $300 million.<blockquote>以电气化为重点的14家SPAC上市电池未来收购(BFAC.U)和Investcorp的Investcorp欧洲收购I(IVCBU)，均筹集了3亿美元。</blockquote> <img src=\"https://static.tigerbbs.com/799a4a1f3d2f8a7ae87a4d79ea13c453\" tg-width=\"481\" tg-height=\"577\" referrerpolicy=\"no-referrer\">Six IPOs submitted initial filings led by leading PE firmTPG(TPG), which filed for an estimated $1.5 billion IPO. ALS biotech&nbsp;Amylyx Pharmaceuticals(AMLX), software firmJustworks(JW), and hypertension biotech&nbsp;CinCor Pharma(CINC) all filed to raise $100 million. Chinese food and beverage supplier&nbsp;Fortune Valley Treasures(FVTI) filed to raise $25 million, and cybersecurity services provider&nbsp;Cerberus Cyber Sentinel(CISO) filed to raise $10 million.<blockquote>由领先私募股权公司牵头的六家IPO提交了初始文件TPG(TPG)，该公司申请了估计15亿美元的IPO。作为生物技术Amylyx制药公司(AMLX)，软件公司Justworks（JW）和高血压生物技术辛科尔制药公司(CINC)均申请筹集1亿美元。中式餐饮供应商财富谷宝藏(FVTI)申请筹集2500万美元，网络安全服务提供商地狱犬网络哨兵（CISO）申请筹集1000万美元。</blockquote> Three SPACs submitted initial filings led by Sagansky and Sloan’s&nbsp;Screaming Eagle Acquisition(SCRMU), which filed to raise $750 million.<blockquote>三家SPAC提交了由Sagansky和Sloan's牵头的初始文件尖叫鹰收购(SCRMU)，申请筹集7.5亿美元。</blockquote> <img src=\"https://static.tigerbbs.com/d7c4fbba2b60c3e616cb443ad97fd1a9\" tg-width=\"710\" tg-height=\"418\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89658/US-IPO-Weekly-Recap-6-IPOs-debut-ahead-of-the-shortened-holiday-week\">renaissancecap...</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOT":"Samsara, Inc.","IMMX":"Immix Biopharma, Inc","GNTA":"Genenta Science S.p.A."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89658/US-IPO-Weekly-Recap-6-IPOs-debut-ahead-of-the-shortened-holiday-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104728154","content_text":"The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara(IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings.\nSamsara priced at the high end to raise $805 million at a $12.4 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22. Samsara finished down 3%.\nItalian solid tumor biotech Genenta Science upsized and priced at the midpoint to raise $36 million at a $208 million market cap. Genenta’s lead candidate, Temferon, is currently in a Phase 1/2a dose-escalation trial in newly diagnosed glioblastoma multiforme patients with unmethylated MGMT gene promoters. The company anticipates completing patient enrollment and treatment by the 2Q22. Genenta finished down 4%.\nWine brand Fresh Vine Wine  priced at the high end to raise $22 million at a $122 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico. Fresh Vine Wine finished down 43%.\nMicro-cap Immix Biopharma priced at the low end to raise $21 million at a $71 million market cap. Immix Biopharma is developing a novel class of tissue-specific therapies in oncology and inflammation. Its lead candidate, IMX-110, is currently in Phase 1b/2a trials for solid tumors in the US and Australia. Immix finished down 20%.\nAustralia-listed Bionomics raised $20 million at an $89 million market cap. Bionomics’ lead candidate, BNC210, is expected to begin its Phase 2 PREVAIL trial for social anxiety disorder by the end of 2021, with topline data anticipated by the end of 2022, and has already started its Phase 2b ATTUNE trial for PTSD, with topline data anticipated in the 1H23. Bionomics finished up 5%.\nMicro-cap satellite developer Sidus Space  priced at the midpoint to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21. Sidus Space finished up 133%.\n14 SPACs went public led by electrification-focused Battery Future Acquisition(BFAC.U) and Investcorp’s Investcorp Europe Acquisition I(IVCBU), which both raised $300 million.\nSix IPOs submitted initial filings led by leading PE firmTPG(TPG), which filed for an estimated $1.5 billion IPO. ALS biotech Amylyx Pharmaceuticals(AMLX), software firmJustworks(JW), and hypertension biotech CinCor Pharma(CINC) all filed to raise $100 million. Chinese food and beverage supplier Fortune Valley Treasures(FVTI) filed to raise $25 million, and cybersecurity services provider Cerberus Cyber Sentinel(CISO) filed to raise $10 million.\nThree SPACs submitted initial filings led by Sagansky and Sloan’s Screaming Eagle Acquisition(SCRMU), which filed to raise $750 million.\n","news_type":1,"symbols_score_info":{"IOT":0.9,"GNTA":0.9,"IMMX":0.9,"VINE":0.9}},"isVote":1,"tweetType":1,"viewCount":2552,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/699427795"}